The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine
Autor: | B. Oosterhuis, Jan H G Jonkman, Jacques A R J Hulsman, Peder Klosterskov Jensen, Malcolm D Eve, Henrieke de Bruin, Alan Richens, Pauline N. M. Van Heiningen |
---|---|
Rok vydání: | 1991 |
Předmět: |
Adult
Male Aging Adolescent medicine.medical_treatment Oxcarbazepine Physiology Pharmacology Elimination rate constant Pharmacokinetics Reference Values medicine Humans Distribution (pharmacology) Pharmacology (medical) Volunteer Active metabolite Aged Aged 80 and over Analysis of Variance Sex Characteristics Dose-Response Relationship Drug business.industry Area under the curve Middle Aged Carbamazepine Anticonvulsant Anticonvulsants business medicine.drug |
Zdroj: | Clinical Pharmacology and Therapeutics. 50:410-419 |
ISSN: | 1532-6535 0009-9236 |
Popis: | The disposition of oxcarbazepine was studied in 12 young and 12 elderly healthy male and 12 young and 12 elderly healthy female volunteers, with emphasis on the influence of age. Oxcarbazepine was administered as a single dose of either 300 mg (men) or 600 mg (women), followed by multiple-dose (300 mg) administration twice a day for 7 days (men) or 6 days (women). Semilogarithmic plasma concentration—time curves showed an increasing decline at decreasing concentrations. Accumulation of the pharmacologically active metabolite monohydroxycarbamazepine was found to be more than one would anticipate on the basis of linear and unchanged pharmacokinetics. Saturation did not seem to occur at the level of renal excretion. No apparent differences between male and female volunteers were observed. A significant higher maximum concentration, higher area under the curve parameters, and a lower elimination rate constant were observed in the elderly. These observations are in line with a smaller renal clearance of monohydroxycarbamazepine in the elderly group. In a clinical situation, these age-related differences are not likely to have important implications. In general, treatment with oxcarbazepine was well tolerated. Clinical Pharmacology and Therapeutics (1991) 50, 410–419; doi:10.1038/clpt.1991.158 |
Databáze: | OpenAIRE |
Externí odkaz: |